Brief: Tarsus To Present Additional Saturn-2 Pivotal Phase 3 Trial Data At The American Academy Of Optometry 2022 Annual Meeting
25/10/2022 15:43
Oct 25 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O :
* TARSUS TO PRESENT ADDITIONAL SATURN-2 PIVOTAL PHASE 3
TRIAL DATA
AT THE AMERICAN ACADEMY OF OPTOMETRY 2022 ANNUAL MEETING
Source text for Eikon: ID:nGNXbzKKNg
Further company coverage: TARS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)